Literature DB >> 29249425

Evidence for functional PAR-4 thrombin receptor expression in cardiac fibroblasts and its regulation by high glucose: PAR-4 in cardiac fibroblasts.

Sonja Kleeschulte1, Johann Jerrentrup2, Daniel Gorski2, Joachim Schmitt2, Anke C Fender3.   

Abstract

BACKGROUND: Thrombin promotes cardiac fibroblast proliferation and fibrosis via protease-activated receptor (PAR-1). PAR-4 is reportedly absent in cardiac fibroblasts. In smooth muscle cells, PAR-4 expression is also low but increases upon hyperglycemia and contributes to vascular remodelling in diabetic mice. We examined if PAR-4 is a glucose-responsive gene with remodelling-related functions in cardiac fibroblasts. METHODS AND
RESULTS: Cardiac PAR-4 increased in mice with streptozotocin- or diabetogenic diet (DD)-induced diabetes. PAR-4 mRNA and protein were detectable in cardiac fibroblasts from chow-fed mice and increased in high (HG, 25mM) vs. low glucose (LG; 5.5mM) cultures. Conversely PAR-4 mRNA was higher in fibroblasts from DD-fed mice but reduced in LG cultures. Cardiac fibroblasts in HG culture responded more strongly to thrombin or PAR-4 activating peptide in terms of migration (wound-scratch assay), remodelling-associated gene expression (interleukin 6, alpha smooth muscle actin) and oxidative stress (dihydroethidium fluorescence).
CONCLUSION: PAR-4 is expressed in mouse cardiac fibroblasts and is dynamically regulated by extracellular glucose in vitro and diabetes in vivo, thereby impacting on fibroblast functions relevant for cardiac remodelling. These findings add further evidence for the usefulness of the recently developed PAR-4 antagonists in clinical settings.
Copyright © 2017 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Keywords:  Cardiac; Diabetes; Fibroblast; High glucose; Protease-activated receptor; Thrombin

Mesh:

Substances:

Year:  2018        PMID: 29249425     DOI: 10.1016/j.ijcard.2017.10.019

Source DB:  PubMed          Journal:  Int J Cardiol        ISSN: 0167-5273            Impact factor:   4.164


  7 in total

1.  Thrombin receptor PAR4 drives canonical NLRP3 inflammasome signaling in the heart.

Authors:  Anke C Fender; Sonja Kleeschulte; Svenja Stolte; Katja Leineweber; Markus Kamler; Johannes Bode; Na Li; Dobromir Dobrev
Journal:  Basic Res Cardiol       Date:  2020-01-07       Impact factor: 17.165

2.  Protease-activated receptor 4 protects mice from Coxsackievirus B3 and H1N1 influenza A virus infection.

Authors:  Kohei Tatsumi; Clare M Schmedes; E Reaves Houston; Emily Butler; Nigel Mackman; Silvio Antoniak
Journal:  Cell Immunol       Date:  2019-07-03       Impact factor: 4.868

3.  Cardiac fibroblast activation and hyaluronan synthesis in response to hyperglycemia and diet-induced insulin resistance.

Authors:  Daniel J Gorski; Anne Petz; Christina Reichert; Sören Twarock; Maria Grandoch; Jens W Fischer
Journal:  Sci Rep       Date:  2019-02-12       Impact factor: 4.379

4.  Angiotensin-II-Evoked Ca2+ Entry in Murine Cardiac Fibroblasts Does Not Depend on TRPC Channels.

Authors:  Juan E Camacho Londoño; André Marx; Axel E Kraft; Alexander Schürger; Christin Richter; Alexander Dietrich; Peter Lipp; Lutz Birnbaumer; Marc Freichel
Journal:  Cells       Date:  2020-01-29       Impact factor: 6.600

Review 5.  The Diabetic Cardiac Fibroblast: Mechanisms Underlying Phenotype and Function.

Authors:  Scott P Levick; Alexander Widiapradja
Journal:  Int J Mol Sci       Date:  2020-02-01       Impact factor: 5.923

6.  PAR-4/Ca2+-calpain pathway activation stimulates platelet-derived microparticles in hyperglycemic type 2 diabetes.

Authors:  Alessandra Giannella; Giulio Ceolotto; Claudia Maria Radu; Arianna Cattelan; Elisabetta Iori; Andrea Benetti; Fabrizio Fabris; Paolo Simioni; Angelo Avogaro; Saula Vigili de Kreutzenberg
Journal:  Cardiovasc Diabetol       Date:  2021-04-03       Impact factor: 9.951

Review 7.  Novel Mechanisms of Anthracycline-Induced Cardiovascular Toxicity: A Focus on Thrombosis, Cardiac Atrophy, and Programmed Cell Death.

Authors:  Silvio Antoniak; Sukanya Phungphong; Zhaokang Cheng; Brian C Jensen
Journal:  Front Cardiovasc Med       Date:  2022-01-17
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.